PMID- 18346994
OWN - NLM
STAT- MEDLINE
DCOM- 20080606
LR  - 20220409
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 23
IP  - 5
DP  - 2008 May
TI  - Characterization of sperm chromatin quality in testicular cancer and Hodgkin's 
      lymphoma patients prior to chemotherapy.
PG  - 1044-52
LID - 10.1093/humrep/den081 [doi]
AB  - BACKGROUND: Although the incidences of testicular cancer and Hodgkin's lymphoma 
      have increased in young men over the past decade, combination chemotherapy has 
      improved survival. As fertility is of importance to these patients, 
      characterization of sperm chromatin structure is needed. We assessed sperm 
      chromatin in testicular cancer and Hodgkin's lymphoma patients prior to 
      chemotherapy, in comparison with control community and idiopathic infertile 
      volunteers. METHODS: DNA damage was assessed with the sperm chromatin structure 
      assay (SCSA), terminal deoxynucleotidyl transferase-mediated dUTP nick end 
      labeling (TUNEL) and comet assays; reactive thiols (SH) and DNA compaction were 
      determined with the monobromobimane (mBBr) and chromomycin A3 (CMA3) assays, 
      respectively. RESULTS: Both testicular cancer (37%) and Hodgkin's lymphoma (81%) 
      patients had normospermic samples with increased DNA damage, compared with 
      controls. Cancer patients also had higher reactive thiols and CMA3 staining, 
      indicating low DNA compaction. CONCLUSIONS: Sperm DNA integrity and compaction 
      were affected in testicular cancer and Hodgkin's lymphoma patients prior to 
      chemotherapy. Although SCSA, TUNEL and comet assays all detected DNA damage, the 
      latter was optimal for use in cancer patients. A combination of the comet assay 
      with tests that evaluate sperm DNA compaction, such as flow cytometry-based CMA3 
      and mBBr assays, is a reliable strategy to characterize sperm chromatin quality 
      in cancer patients at the time of sperm banking.
FAU - O'Flaherty, C
AU  - O'Flaherty C
AD  - Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, 
      Canada.
FAU - Vaisheva, F
AU  - Vaisheva F
FAU - Hales, B F
AU  - Hales BF
FAU - Chan, P
AU  - Chan P
FAU - Robaire, B
AU  - Robaire B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080317
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - 0 (Bridged Bicyclo Compounds)
RN  - 0 (Chromatin)
RN  - DVW027E7NL (Chromomycin A3)
RN  - V23UK0CYXL (monobromobimane)
SB  - IM
MH  - Adult
MH  - Bridged Bicyclo Compounds
MH  - Chromatin/*ultrastructure
MH  - Chromomycin A3
MH  - Cohort Studies
MH  - Comet Assay
MH  - *DNA Damage
MH  - Flow Cytometry
MH  - Hodgkin Disease/*physiopathology
MH  - Humans
MH  - In Situ Nick-End Labeling
MH  - Infertility, Male/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Sensitivity and Specificity
MH  - Spermatozoa/*ultrastructure
MH  - Testicular Neoplasms/*physiopathology
EDAT- 2008/03/19 09:00
MHDA- 2008/06/07 09:00
CRDT- 2008/03/19 09:00
PHST- 2008/03/19 09:00 [pubmed]
PHST- 2008/06/07 09:00 [medline]
PHST- 2008/03/19 09:00 [entrez]
AID - den081 [pii]
AID - 10.1093/humrep/den081 [doi]
PST - ppublish
SO  - Hum Reprod. 2008 May;23(5):1044-52. doi: 10.1093/humrep/den081. Epub 2008 Mar 17.